|
|
Post by blindhog1 on Feb 15, 2016 21:24:36 GMT -5
Peppy, as you know I'm in a 5 year study with Novartis. It's for old cardiac cripples that also have diabetes. I have been getting a lot of attention recently with my numbers since I've been taking Afrezza. Since I don't have a CGM I keep daily records. At first I submitted copies monthly. After awhile they asked for the originals instead of copies. Fortunately I kept all these notes because of Afrezza and my ENDO...I could have cared less about Novartis. No one wants to talk to me but my numbers are real...and they know it.  Can you please give more details on what exactly the study is? getting on afrezza and having normalized blood sugars is doing wonders.. Jackie reported her eyevision and retinopathy is improved, some one else reported their cholesterol numbers have become better and another is off their heart meds.... Try and keep up. I've already laid out the details. What is your function here..."Village Idiot"? |
|
|
|
Post by jerrys on Feb 15, 2016 22:39:52 GMT -5
Check this out. This is already approved by European regulators with the CE-Certified. This article was from December 2015. it also mentions a US Firm working on the same type of device. (Cohero Health). Again it would be great if MannKind could provide as part of the Doctor Sample Kit this simple Spirometer for Doctor use only. Makes it easy and economical if the cost is about $24.00 each then it would be a nominal cost for MannKind to include in the Doctor kit. Doctor uses the Spirometer and then gives the Patient the 30 day Afrezza Sample Pack with the 800 number to the Afrezza specialist to give the patient information on how to use the product properly.
medcitynews.com/2015/12/swedish-design-firm-pond-healthcare-collaborates-with-novartis-on-smart-spirometer/
Health IT, Pharma
Swedish design firm Pond Healthcare collaborates with Novartis on smart spirometer
By Stephanie Baum
Dec 4, 2015 at 2:39 PM
pond novartis air spirometerSwedish design firm Pond Healthcare Innovation has developed apps for pharmaceutical companies focusing on the European market supporting patients and clinicians. It developed a symptom tracker to support multiple sclerosis patients for Novartis and a training tool for physicians on Hyponatremia for Otsuka. Its latest collaboration with Novartis is a smart spirometer and companion app designed to evaluate lung function.
The goal of these devices is to get a regular assessment of lung function so if there is a sudden change, physicians can intervene faster and reduce the need for hospitalization.
Pond Healthcare Innovation CEO Daniel Taub said in an interview that the Air Smart spirometer device is CE-certified by European regulators and is available in Europe. Taub said that it collaborated with Novartis’s on a COPD application for the device, but he believes it could be applied to a broader variety of respiratory conditions beyond Europe.
It plans to launch a version of the smartphone-enabled device for Android users in the first quarter of 2016. The company is also working on an application to diagnose asthma.
It reflects a broader Beyond the Pill collaboration trend between pharma and digital health companies to add services and connected devices to improve patient outcomes. Cohero Health developed a smart spirometer for the U.S. market for people with respiratory problems.
Novartis did not immediately respond to a request for comment before this post was published.
There have been a number of portable phone linked spirometers in development the past few years -- e.g. myspiroo, respi, spirosmart. None appear to have made much headway in the market. However, that misses an essential point with respect to afrezza. Once a doctor documents the results of a spirometry test in a patient's chart, that doc becomes responsible for assessing the results and deciding on the appropriate follow up. A typical endo does not want that responsibility, least of all for the sole purpose of prescribing a drug. Legally, the endo -- or any doc for that matter -- must meet the same standard of care as a pulmonologist when interpreting a lung test and deciding on appropraite follow up. It takes only one mistake to set off a malpractice suit. A pulmonologist gets up on a witness stand and says this endo didn't interpret the test correctly and the endo's malpractice premiums skyrocket. Note the endo could not defer to the iphone and blame it for misinterpreting the test. Indeed, that would look even worse! Imagine trying to explain to a jury that you let your phone interpret tests for you! If anything is going to work to handle the spirometry issue, it will have to involve pulmonologists in the chain somewhere. |
|
|
|
Post by dreamboatcruise on Feb 15, 2016 23:21:15 GMT -5
jerrys... many primary care docs perform the relatively simple test required for Afrezza with no pulmonologist in the chain. Some endos may not want to bother with it, but I certainly think your characterization of the malpractice risk is overblown. If the test came in as anything other than normal, the endo would undoubtedly recommend following up with the patients primary or a specialist and put themselves in the role of treating that ailment.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 15, 2016 23:21:16 GMT -5
Can you please give more details on what exactly the study is? getting on afrezza and having normalized blood sugars is doing wonders.. Jackie reported her eyevision and retinopathy is improved, some one else reported their cholesterol numbers have become better and another is off their heart meds.... Try and keep up. I've already laid out the details. What is your function here..."Village Idiot"? thx..I will end that there |
|
|
|
Post by mnkdorbust on Feb 15, 2016 23:37:41 GMT -5
Apology in advance as i'm being lazy and not digging back to any transcript of the 2015 shareholders meeting. Didn't Al mention that he had found a cheap spirometer option during the meeting last year? Curious if this could have been what he was talking about. Just throwing it out there.
|
|
|
|
Post by jerrys on Feb 16, 2016 11:11:56 GMT -5
jerrys ... many primary care docs perform the relatively simple test required for Afrezza with no pulmonologist in the chain. Some endos may not want to bother with it, but I certainly think your characterization of the malpractice risk is overblown. If the test came in as anything other than normal, the endo would undoubtedly recommend following up with the patients primary or a specialist and put themselves in the role of treating that ailment. One thing that would be helpful would be to simply survey the endos an see why they oppose utilizing spirometry. As best I can tell, that has never been done. My own opinion is that it's not simply the malpractice risk; it's the malpractice exposure just so a patient can get a drug classified as non-inferior. Why assume such a risk when you have lung test free alternatives? |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 16, 2016 11:49:01 GMT -5
These threads are pointless IMO.
Buyout speculation is a fart in the wind until rights are handed over back to MNKD. No one is putting in any bid without looking at the trial data that SNY still has. Outside of some really big news this will have some nice swings until the summer between .90- 1.05
|
|
